CureVac N.V (CVAC): Price and Financial Metrics
CVAC Price/Volume Stats
|Current price||$5.52||52-week high||$12.79|
|Prev. close||$5.42||52-week low||$4.95|
|Day high||$5.60||Avg. volume||710,294|
|50-day MA||$5.69||Dividend yield||N/A|
|200-day MA||$7.90||Market Cap||1.24B|
CVAC Stock Price Chart Interactive Chart >
CureVac N.V (CVAC) Company Bio
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.(Source:Wikipedia)
CVAC Latest News Stream
|Loading, please wait...|
CVAC Latest Social Stream
View Full CVAC Social Stream
Latest CVAC News From Around the Web
Below are the latest news stories about CUREVAC NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 191.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings and welcome to the CureVac Financial Results for Third Quarter and First Nine Months of 2023 Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, […]
CureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 37%, while individual investors hold 31%
Key Insights The considerable ownership by private equity firms in CureVac indicates that they collectively have a...
Q3 2023 CureVac NV Earnings Call
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early ...
CVAC Price Returns